Summary:
In lower risk MDS with anemia, having at least 3 somatic mutations can predict lower erythroid response to ESA, but not in multivariate analysis. Having at least 3 mutations predicts worse survival independently of IPSS-R.
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Erythropoiesis stimulating agents (ESA) are generally first line treatments of anemia in lower risk myelodysplastic syndrome (MDS), yielding response rates of 30 to 60%, median response duration of 20 to 24 months 1,2 and a possible survival improvement compared to RBC transfusions alone [1] [2] [3] . Main consensus prognostic factors of better response to ESA include low or int-1 IPSS, low RBC transfusion burden, and low serum EPO (sEPO) 4 . Other reported prognostic factors for response to ESA include marrow multilineage dysplasia, flow cytometry scoring 5 , ERK and STAT5 phosphorylation in erythroblasts 6, 7 , and IPSS-R 8 .
Somatic mutations are found in up to 80% of MDS. Mutational analysis of the 37 most frequently mutated genes in MDS (listed in Sup stopgain and 7 splicing mutations. 86% of the patients had at least one mutation (median number of mutations 2, range 0-6).
Mutations were found in more than 10% of the patients for SF3B1 (40.5% of the Table 2 ) and involved splicing factors (SF3B1, SRSF2, In univariate analysis (Table 1) , male gender (p=0.03), sEPO level >100U/L (best discriminant threshold in this study) (p = 0.002), and intermediate IPSS-R (p= 0.02) were significantly correlated with worse HI-E, while RBC-TD had borderline significance (p = 0.058), and Hb level, platelet count, ANC, age, karyotype and importance of dysplasia (after central review) had no significant prognostic impact.
HI-E was 73% and 63% in patients with no mutation, and at least one mutation, respectively (p= 0.44). HI-E was 74% in the 51 patients with ≤ 2 mutations versus 46% in the 28 patients with >2 mutations ( p= 0.01) ( Table 1 ). The cut-off point of 3 mutations was chosen because HI-E was 73%, 71%, 79%, 47%, 38%, in patients with 0, 1, 2, 3 and compared with 63% of the patients with ≤ 2 mutations (p=0.01). HI-E was 57% and 65% in patients with mutational pattern 1 (one major clone) and mutational pattern 2 (major and minor subclones), respectively (p= 0.62).
Individual mutation of the most frequently mutated genes (SF3B1, TET2, ASXL1, DNMT3A), or mutation in a particular gene category (DNA methylation, chromatin modifier, splicing factor,transcription factors, signalling pathways or mutation of the following genes associated with poor OS in MDS ( ASXL1, TP53, RUNX1) had no significant impact on HI-E (Sup Table 2 ). In particular, HI-E was 58% in the 32 patients with SF3B1 mutation (31 of whom had received ESA without G-CSF,) versus 68% in patients without SF3B1 mutation (p=0.4).
In an adjusted logistic regression model, male gender, sEPO level>100U/L, RBC-TD and IPSS-R, but not the number of mutations or presence of mutations in a particular gene category were significantly correlated with HI-E ( Figure S2A ). Increasing number of mutations correlated with worse OS (p=0.01, Figure S2B ). In multivariate analysis, IPSS-R and >2 mutations significantly and independently influenced OS (Table 2) .
In this first next generation sequencing study of lower risk MDS patients treated by ESA, to our knowledge, having >2 somatic mutations was associated with lower HI-E. While previous studies have shown the prognostic value of somatic mutations in MDS (irrespective of treatment, or with hypomethylating agents or allogeneic SCT) 9, 10 , their predictive role on response to ESA had not been studied. In the present series, the response rate to ESA was relatively high (64.5%), probably due to the fact that all patients had lower risk MDS, had serum EPO level < 500 U/l, were generally not RBC TD and received high ESA dose (EPO 60000 IU/week of EPO, 250-300µg/week or darbepoietin Supplemental data: The comparison of the VAF of each mutated gene in each individual reveals 2 types of clonal patterns. For every VAF mutation, depth was considered to calculate 95% confidence intervals calculated using a Wilson test based on binomial distribution. In patients harboring at least 2 mutations, the clonal heterogeneity was evaluated by  2 test to determine if the VAF were significantly different or not. In the former situation, the mutations with significantly higher VAF were considered as major (major mut), and the other ones as minor (minor mut). In patients with only one mutation, this mutation was considered as major by the absence of other mutations among the genes tested. 45 patients had only one major clone containing 1 to 5 major mutations (pattern 1), 34 had a major subclone and one or two minor subclones (pattern
